These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
694 related articles for article (PubMed ID: 8313389)
1. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Gabizon A; Catane R; Uziely B; Kaufman B; Safra T; Cohen R; Martin F; Huang A; Barenholz Y Cancer Res; 1994 Feb; 54(4):987-92. PubMed ID: 8313389 [TBL] [Abstract][Full Text] [Related]
2. Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors: the relation between pharmacokinetic property and toxicity. Hong RL; Tseng YL Cancer; 2001 May; 91(9):1826-33. PubMed ID: 11335910 [TBL] [Abstract][Full Text] [Related]
3. Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: a pediatric oncology group study. Marina NM; Cochrane D; Harney E; Zomorodi K; Blaney S; Winick N; Bernstein M; Link MP Clin Cancer Res; 2002 Feb; 8(2):413-8. PubMed ID: 11839657 [TBL] [Abstract][Full Text] [Related]
4. Direct injection of liposome-encapsulated doxorubicin optimizes chemomyectomy in rabbit eyelid. McLoon LK; Wirtschafter JD Invest Ophthalmol Vis Sci; 1999 Oct; 40(11):2561-7. PubMed ID: 10509650 [TBL] [Abstract][Full Text] [Related]
5. Comparative study of the antitumor activity of free doxorubicin and polyethylene glycol-coated liposomal doxorubicin in a mouse lymphoma model. Cabanes A; Tzemach D; Goren D; Horowitz AT; Gabizon A Clin Cancer Res; 1998 Feb; 4(2):499-505. PubMed ID: 9516942 [TBL] [Abstract][Full Text] [Related]
6. Factors affecting the accelerated blood clearance of polyethylene glycol-liposomes upon repeated injection. Laverman P; Carstens MG; Boerman OC; Dams ET; Oyen WJ; van Rooijen N; Corstens FH; Storm G J Pharmacol Exp Ther; 2001 Aug; 298(2):607-12. PubMed ID: 11454922 [TBL] [Abstract][Full Text] [Related]
7. Phase 1 clinical study of pegylated liposomal doxorubicin (JNS002) in Japanese patients with solid tumors. Fujisaka Y; Horiike A; Shimizu T; Yamamoto N; Yamada Y; Tamura T Jpn J Clin Oncol; 2006 Dec; 36(12):768-74. PubMed ID: 17095524 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma. Huang SK; Mayhew E; Gilani S; Lasic DD; Martin FJ; Papahadjopoulos D Cancer Res; 1992 Dec; 52(24):6774-81. PubMed ID: 1458465 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study. Mross K; Niemann B; Massing U; Drevs J; Unger C; Bhamra R; Swenson CE Cancer Chemother Pharmacol; 2004 Dec; 54(6):514-24. PubMed ID: 15322827 [TBL] [Abstract][Full Text] [Related]
10. Polyethylene glycol-complexed cationic liposome for enhanced cellular uptake and anticancer activity. Jung SH; Jung SH; Seong H; Cho SH; Jeong KS; Shin BC Int J Pharm; 2009 Dec; 382(1-2):254-61. PubMed ID: 19666094 [TBL] [Abstract][Full Text] [Related]
11. Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Gabizon AA Cancer Res; 1992 Feb; 52(4):891-6. PubMed ID: 1737351 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products? Mamidi RN; Weng S; Stellar S; Wang C; Yu N; Huang T; Tonelli AP; Kelley MF; Angiuoli A; Fung MC Cancer Chemother Pharmacol; 2010 Nov; 66(6):1173-84. PubMed ID: 20661737 [TBL] [Abstract][Full Text] [Related]
13. Phase I study of doxil-cisplatin combination chemotherapy in patients with advanced malignancies. Lyass O; Hubert A; Gabizon AA Clin Cancer Res; 2001 Oct; 7(10):3040-6. PubMed ID: 11595693 [TBL] [Abstract][Full Text] [Related]
14. Accumulation of liposomal lipid and encapsulated doxorubicin in murine Lewis lung carcinoma: the lack of beneficial effects by coating liposomes with poly(ethylene glycol). Parr MJ; Masin D; Cullis PR; Bally MB J Pharmacol Exp Ther; 1997 Mar; 280(3):1319-27. PubMed ID: 9067319 [TBL] [Abstract][Full Text] [Related]
15. In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice. Gabizon A; Horowitz AT; Goren D; Tzemach D; Shmeeda H; Zalipsky S Clin Cancer Res; 2003 Dec; 9(17):6551-9. PubMed ID: 14695160 [TBL] [Abstract][Full Text] [Related]
16. Liposomes and hyperthermia in mice: increased tumor uptake and therapeutic efficacy of doxorubicin in sterically stabilized liposomes. Huang SK; Stauffer PR; Hong K; Guo JW; Phillips TL; Huang A; Papahadjopoulos D Cancer Res; 1994 Apr; 54(8):2186-91. PubMed ID: 8174126 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Gabizon A; Shmeeda H; Barenholz Y Clin Pharmacokinet; 2003; 42(5):419-36. PubMed ID: 12739982 [TBL] [Abstract][Full Text] [Related]
18. Caelyx/Doxil for the treatment of metastatic ovarian and breast cancer. Tejada-Berges T; Granai CO; Gordinier M; Gajewski W Expert Rev Anticancer Ther; 2002 Apr; 2(2):143-50. PubMed ID: 12113236 [TBL] [Abstract][Full Text] [Related]
19. Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial? Hong RL; Huang CJ; Tseng YL; Pang VF; Chen ST; Liu JJ; Chang FH Clin Cancer Res; 1999 Nov; 5(11):3645-52. PubMed ID: 10589782 [TBL] [Abstract][Full Text] [Related]
20. Phase I clinical and pharmacological study of liposome-entrapped NDDP administered intrapleurally in patients with malignant pleural effusions. Perez-Soler R; Shin DM; Siddik ZH; Murphy WK; Huber M; Lee SJ; Khokhar AR; Hong WK Clin Cancer Res; 1997 Mar; 3(3):373-9. PubMed ID: 9815694 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]